Navigation Links
Locus Biosciences Secures $5m Convertible Note for CRISPR-Cas3 Antimicrobials
Date:7/10/2017

RESEARCH TRIANGLE PARK, N.C., July 10, 2017 /PRNewswire/ -- Locus Biosciences Inc. today announced the closing of a $5m Convertible Note to support the development of CRISPR-Cas3 antimicrobial therapeutics. Financing for the round was led by Tencent Holdings Limited, a leading Chinese Internet services provider, and joined by the North Carolina Biotechnology Center. This funding will advance multiple infectious disease product programs targeting antibiotic resistant infections and other microbiome-related diseases.

Founded by Dr. Rodolphe Barrangou and Dr. Charles Gersbach, Locus Biosciences designs and creates novel antimicrobial applications which leverage the powerful CRISPR-Cas3 system that kills target bacteria by irreversibly destroying the bacterial DNA. Unlike efforts to use CRISPR-Cas9 and other technologies to edit the human genome, Locus is taking advantage of the unique properties of CRISPR-Cas3 to target and eradicate specific bacterial populations. Locus believes this technology is a catalyst for new infectious disease and microbiome therapies while simultaneously addressing the challenges coupled with broad-spectrum antibiotics and the selection for antibiotic resistance.

Locus Biosciences is using CRISPR-Cas3 technology to target antibiotic resistant infections without risks associated with targeting human cells. "Our novel CRISPR-Cas3 approach to precision antimicrobials works by commandeering a bacterial cell immune system present in many bacteria, so we never modify human cells," said Rodolphe Barrangou, PhD., CSO of Locus Biosciences. "This makes our technology ideal for addressing pathogenic targets throughout the microbiome while avoiding currently known antibiotic resistance mechanisms and leaving non-target bacteria and human cells unharmed." 

Scientists at Locus Biosciences are now advancing their work with CRISPR-Cas3 to develop antimicrobials to take on diseases such as C. difficile and CRE infections. "As the only company in the world using CRISPR-Cas3 enzymes to kill targeted pathogens, we believe Locus could have the world's most powerful mechanism of action to drive programmed cell death in bacterial targets," says Paul Garofolo, CEO of Locus Biosciences. "Not only could this technology revolutionize the way we treat multi-drug resistant infections in patients, but it could also catalyze a novel and powerful approach to changing the human microbiome." 

About Locus Biosciences

Locus Biosciences is an emerging biotechnology company focused on the discovery and development of a next generation CRISPR-Cas platform for precision antimicrobials.  Our novel approach to precision antimicrobials works by taking advantage of an immune system present in many bacteria called the CRISPR-Cas system.  Locus designs and creates novel CRISPR RNAs (guide RNAs) that direct the powerful Cas3 nuclease to target and kill bacteria cells by irreversibly destroying DNA. The irreversible destruction of DNA is the primary differentiator between Cas3 and the more widely known Cas9 enzyme used for gene editing and repair.  Locus has exclusive rights to the use of the novel Type I CRISPR-Cas3 platform, a programmable system that destroys DNA efficiently, specifically and beyond repair.

The Locus Biosciences platform enables the design and development of powerful antimicrobials that avoid currently known antibiotic resistance mechanisms while leaving non-target bacteria unharmed. Built on prokaryotic technology for prokaryotic targets, Locus is advancing its platform to create therapeutics for critical disease areas ranging from resistant bacterial infections to the microbiome.

View original content with multimedia:http://www.prnewswire.com/news-releases/locus-biosciences-secures-5m-convertible-note-for-crispr-cas3-antimicrobials-300485134.html


'/>"/>
SOURCE Locus Biosciences Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Therapix Biosciences to Ring the Nasdaq Stock Market Opening Bell on June 28
2. Therapix Biosciences to Present at Upcoming Scientific and Investor Conferences in June
3. Therapix Biosciences Ltd. Announces Full Exercise of Underwriters Over-Allotment Option
4. 3-V Biosciences to Present Data at the AACR 2017 Annual Meeting in Washington, DC
5. Avelas Biosciences to Present at Needham & Company 16th Annual Healthcare Conference
6. Therapix Biosciences Ltd. Announces Closing of U.S. Initial Public Offering of American Depositary Shares; 2,000,000 American Depository Shares Priced at $6.00 per ADS
7. Therapix Biosciences Ltd. Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing
8. Pressure BioSciences, Inc. Discusses Research Market, Goals and Milestones for First Half of 2017 in New SNNLive Video Interview with StockNewsNow.com
9. Neurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2016 Results
10. How These Generic Drugs Stocks are Faring? -- Neurocrine Biosciences, Evoke Pharma, SCYNEXIS, and Eagle Pharma
11. Hope Biosciences Acquires Worldwide Rights To Novel MERTK/AXL Inhibitor From NeoPharm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... -- It should come as no surprise to anyone that ... midst of a crippling opioid epidemic. According to the ... overdose deaths from opiate-based medications has quadrupled, Says, Dr. ... from 2001 to 2015". During this time, the prescription rate ... drawing a compelling link between prescription and eventual addiction. The ...
(Date:7/13/2017)... -- RK Logistics Group, Inc. was awarded California ... Fremont, CA headquarters facility where it provides ... San Jose for hi-tech, pharmaceutical and biomedical ... with its Fremont Innovation District, is excited to strategically partner ... to the hundreds of biotech, pharma and biomed companies throughout ...
(Date:7/12/2017)... -- CarpalAID is a revolutionary new product that relieves painful carpal ... tunnel syndrome affects more than 8 million people a year. Women ... The common methods of treating CTS are painful surgery, the use ... gloves. ... CarpalAID is a clear patch worn on the palm of the ...
Breaking Medicine Technology:
(Date:7/25/2017)... ... 25, 2017 , ... USHEALTH Group, Inc. has been announced ... World Awards®. The coveted annual CEO World Awards program encompasses the world’s best ... social responsibility, and milestones from every major industry in the world. Organizations from ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... (407) 916-7235, kklaproth(at)robinsmorton(dot)com , Robins & Morton, Perkins Will, Newcomb & Boyd, ... topping out of the new Destination Medical Building located at Mayo Clinic ...
(Date:7/24/2017)... CA (PRWEB) , ... July 24, 2017 , ... Cosmetic ... spotlight doctors and the cosmetic surgeries they perform on a daily basis. , ... the cosmetic surgery procedures they specialize in at their practices. , When asked ...
(Date:7/24/2017)... ... 24, 2017 , ... A four alarm fire in an ... threatened numerous homes and businesses nearby, causing some 700 individuals to be evacuated, ... Area consulting firm Fire Protection Group, Inc. notes that the report is a ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... Every year, ... invigorating and educational conference, InstructureCon. Each annual event is coupled with a dynamic theme ... with a James Bond theme, Mission: InstructureCon 0017. , To extend their partnership ...
Breaking Medicine News(10 mins):